A similar meta-analysis in NSCLC, urothelial cancer and HNSCC showed that smokers benefited from anti PD-1/PD-L1 mono or combination therapy while nonsmokers benefitted from a combination of chemo- and immunotherapy [122]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.